Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Edity Therapeutics logo — Using human immune cells to deliver therapeutic proteins

Edity Therapeutics

Using human immune cells to deliver therapeutic proteins

Founded 2020 Israel Israel 22 employees Seed Biotechnology, Health and Wellness +1

General Information

Company Name Edity Therapeutics
Founded Year 2020
Location Israel Israel +1
Founders / Decision Makers
Team member
Employees 22
Industries Biotechnology, Health and Wellness, Medical Devices
Funding Stage Seed
Social

Get notified when Edity Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Edity Therapeutics

Edity Therapeutics, established in 2020, is a biotechnology startup hailing from Israel that is making waves with its pioneering approach to using human immune cells for delivering therapeutic proteins. The company's platform offers a revolutionary way to transfer these proteins to the target cells of patients, enabling precise modulation of intracellular pathways of diseases. By leveraging gene editors, immune sensors, enzymes, and intrabodies, Edity is at the forefront of advancing the potential for protein-based treatments. The startup recently secured a Seed Round investment on 12 July 2022, with backing from notable investors including Reinforced Ventures and NFX Bio. This injection of funding positions Edity Therapeutics to further develop its groundbreaking technology and drive impact within the realm of health and wellness, as well as medical devices.

Taxonomy: gene editing, cell therapy, immune cells, therapeutic proteins, drug delivery, in-vivo gene editing, T-cells, cancer, intracellular pathways, target cells, enzyme therapy, immunotherapy, innovation, startup

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round •••••• 2
Investor
•••• •••• 		12 Jul 2022
Seed Round •••••• 1
Investor
01 Mar 2021
Pre Seed Round •••••• 1 •••• •••• 01 Jan 2020

Edity Therapeutics Alternatives & Competitors

Edity Therapeutics vs
Immusoft
Immusoft United States

Cell therapy company dedicated to improving the lives of patients with rare diseases

Grant
22 employees
Biotechnology, Health Care
Edity Therapeutics vs
ExpressCells
ExpressCells United States

Using genetic engineering to create knock-in cell lines for biological research

Series Unknown
2-10 employees
Biotechnology
Edity Therapeutics vs
Sana Biotechnology, Inc.
Sana Biotechnology, Inc. United States

Focused on creating and delivering engineered cells as medicines for patients

IPO
257 employees
Biotechnology, Health Care

FAQ About Edity Therapeutics

Using human immune cells to deliver therapeutic proteins
Edity Therapeutics was founded in 2020.
Edity Therapeutics is headquartered in Israel.
Edity Therapeutics operates in the following industries: Biotechnology, Health and Wellness, Medical Devices.
Edity Therapeutics has approximately 22 employees.
Edity Therapeutics has completed 3 funding rounds. The latest funding stage is Seed.
Top alternatives and competitors to Edity Therapeutics include Immusoft, ExpressCells, Sana Biotechnology, Inc., Vectalys, Smart Immune. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Edity Therapeutics and Immusoft are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Edity Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy